Contact this trialFirst, we need to learn more about you.
Vedolizumab + Tofacitinib for Ulcerative Colitis
Recruiting3 awardsPhase 4
Asheville, North Carolina
This trial will test the effectiveness of vedolizumab+tofacitinib and vedolizumab alone in treating adults with moderate-severe UC. Participants will receive vedolizumab+tofacitinib for 8 weeks and then be monitored for response. Those who show response will receive vedolizumab alone for 44 weeks.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service